Cargando…

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

INTRODUCTION: Fibroblast activation protein (FAP) is highly overexpressed in stromal tissue of various cancers. While FAP has been recognized as a potential diagnostic or therapeutic cancer target for decades, the surge of radiolabeled FAP-targeting molecules has the potential to revolutionize its p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Privé, Bastiaan M., Boussihmad, Mohamed A., Timmermans, Bart, van Gemert, Willemijn A., Peters, Steffie M. B., Derks, Yvonne H. W., van Lith, Sanne A. M., Mehra, Niven, Nagarajah, James, Heskamp, Sandra, Westdorp, Harm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199876/ https://www.ncbi.nlm.nih.gov/pubmed/36813980 http://dx.doi.org/10.1007/s00259-023-06144-0

Ejemplares similares

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
por: Uijen, M. J. M., et al.
Publicado: (2021)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

An Explorative Study of the Incidental High Renal Excretion of [(18)F]PSMA-1007 for Prostate Cancer PET/CT Imaging
por: Allach, Youssra, et al.
Publicado: (2022)

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
por: Banda, Amina, et al.
Publicado: (2022)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
por: Peters, Steffie M. B., et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
por: Peters, Steffie M. B., et al.
Publicado: (2021)

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
por: Rosar, Florian, et al.
Publicado: (2022)

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of (177)Lu‐PSMA‐617 in prostate cancer patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2022)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Creemers, Jeroen H. A., et al.
Publicado: (2021)

Targeted Radionuclide Therapy of Cancer and Infections
por: van der Wal, Bart C. H., et al.
Publicado: (2023)

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
por: Wierstra, Peter, et al.
Publicado: (2019)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023)

International Committee for Radionuclide Metrology Symposium on Radionuclide Metrology and its Applications
por: Bortel, G, et al.
Publicado: (1994)

Evaluating the impact of resident involvement during the laparoscopic nephrectomy
por: Privé, Bastiaan, et al.
Publicado: (2019)

Which triggers could support timely identification of primary antibody deficiency? A qualitative study using the patient perspective
por: Janssen, Lisanne M. A., et al.
Publicado: (2021)

An international multi-center investigation on the accuracy of radionuclide calibrators in nuclear medicine theragnostics
por: Saldarriaga Vargas, Clarita, et al.
Publicado: (2020)

Natural radionuclide and radiological assessment of building materials in high background radiation areas of Ramsar, Iran
por: Bavarnegin, Elham, et al.
Publicado: (2013)

Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
por: van Lith, Sanne A.M., et al.
Publicado: (2022)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

Radionuclides and Radiation Indices of High Background Radiation Area in Chavara-Neendakara Placer Deposits (Kerala, India)
por: Derin, Mary Thomas, et al.
Publicado: (2012)

Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018)

Adriamycin cardiotoxicity monitoring by radionuclide scan.
por: Robinson, B. A., et al.
Publicado: (1983)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

Combination Strategies to Improve Targeted Radionuclide Therapy
por: Chan, Tiffany G., et al.
Publicado: (2020)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Progressive Pulmonary Artery Dilatation is Associated with Type B Aortic Dissection in Patients with Marfan Syndrome
por: Brouwer, Christel, et al.
Publicado: (2019)

Engineered mineralogical interfaces as radionuclide repositories
por: Douglas, G. B., et al.
Publicado: (2023)

General Discussion on Medical Radionuclides
por: Qaim, S M
Publicado: (2019)

Multiagent imaging of inflammation and infection with radionuclides
por: Palestro, Christopher J., et al.
Publicado: (2013)

Manual of bioassay procedures for radionuclides
por: Pleskach, S, et al.
Publicado: (1986)

Radionuclide imaging of bone marrow disorders
por: Agool, Ali, et al.
Publicado: (2010)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tlmm5u6gbbcs3trg4p3phg37v4